US FDA approves AstraZeneca-Merck’s Lynparza to treat early-stage breast cancer
The approval was based on results from a late-stage study in which the drug showed statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences and second cancers or death by 42 per cent compared with placebo
AstraZeneca has said the US Food and Drug Administration (FDA) approved its cancer drug, jointly developed with US-based Merck & Co, as a treatment for patients with early-stage breast cancer with certain mutations.
The company also said that the drug, Lynparza, was approved for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery.
The approval was based on results from a late-stage study in which the drug showed statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences and second cancers or death by 42 per cent compared with placebo.
Lynparza leads a class of drugs known as PARP inhibitors, which keep cancer cells damaged by chemotherapy from repairing themselves. It is a key asset for AstraZeneca with approvals for ovarian, prostate and pancreatic cancers.
Following the US approval for Lynparza, AstraZeneca will receive a regulatory milestone payment of $175 million from Merck.
Edits by EP News Bureau
- Advertisement -
thank you very nice website article
I was once a patient diagnosed with Pancreatic Cancer. I was cured naturally with the use of Sims Gomez Herbs formula.